Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Gilead Sciences, Inc.'s ( NASDAQ:GILD ) recent soft profit numbers didn't appear to worry shareholders, as the ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

Gilead Sciences has a better P/E ratio of 305.37 than the aggregate P/E ratio of 65.67 of the Biotechnology industry. Ideally, one might believe that Gilead Sciences Inc. might perform better in the ...

The healthcare sector continues to advance with technological breakthroughs and growing demand for medical services, creating ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the preceding trading day.

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply ...